| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Operating Officer | Director
1 company
Kelly Paul Edward serves as a Chief Operating Officer at RLMD. Across recent SEC filings that breaks down to 19 buys and 17 sells. Those positions are worth an estimated $1.1M at current prices.
Historically, Kelly Paul Edward's trades have earned a middling insider score of 67/100 across 4 rated trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of +49.3%.
The biggest single holding is RLMD (~$1.1M) as Chief Operating Officer. Net of sales, the recent Form 4 record there shows accumulation of 550,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Oct 18, 2019 | RLMD Relmada Therapeutics, Inc. | Director | Buy | 5,000 | $19.14 | $95,685.00 | +4.1% | |
| May 14, 2019 | RLMD Relmada Therapeutics, Inc. | Director | Buy | 100,000 | $1.50 | $150,000.00 | +25.7% | |
| Dec 11, 2018 | RLMD Relmada Therapeutics, Inc. | Director | Buy | 5,000 | $1.21 | $6,065.00 | +1.3% | |
| Oct 12, 2018 | RLMD Relmada Therapeutics, Inc. | Director | Buy | 150,000 | $0.90 | $135,000.00 | +1,500% | |
| Dec 14, 2015 | RLMD Relmada Therapeutics, Inc. | Director | Buy | 10,000 | $2.91 | $29,055.00 | New |